Lithium treatment reduces the renal kallikrein excretion rate.
Lithium salts are widely used agents for the prophylactic treatment of affective disorders. Lithium salts may be associated with distal nephron dysfunction. Kallikrein is a protease which is generated by the distal nephron. We used an amidolytic assay of chromatographically purified enzyme to determine the urinary excretion rate of active kallikrein in relation to lithium treatment. All plasma lithium concentrations were within the therapeutic range (0.4 to 0.9 mmol/liter). In 15 patients the urinary excretion rate of active kallikrein was 267.4 +/- 65.6 mU/24 hrs before lithium treatment, and fell to 117.8 +/- 39.6 mU/24 hrs (P less than 0.05) on day 14 of lithium treatment. This reduction was associated with a decrease of immunoreactive kallikrein in the same urines by 66%. In another 15 patients who had undergone lithium therapy for an average period of 5.6 years, the urinary excretion rate of active kallikrein was 86.1 +/- 14.5 mU/24 hrs, while 21 age-matched healthy controls had an excretion rate of 364.1 +/- 58.4 mU/24 hrs (P less than 0.05). Measurements of immunoreactive kallikrein in the same urine samples demonstrated a reduction of kallikrein after long-term lithium treatment by 78%. These observations could not be attributed to changes in creatinine clearance, renal sodium or potassium excretion rates or plasma concentrations of aldosterone and vasopressin. Addition of lithium to the urine in vitro had no demonstrable effect on kallikrein measurement by amidolytic assay. We conclude that lithium in therapeutic plasma concentrations may directly suppress the secretion of kallikrein by renal connecting tubule cells.
Gross
P
P
Department of Medicine, University of Heidelberg, Federal Republic of Germany.
Reinhard
C
C
Marin-Grez
M
M
Fink
E
E
Sauer
H
H
D000328:Adult; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000652:urine; D003864:Depression, Chemical; D005260:Female; D006801:Humans; D007610:Kallikreins / Q000652:urine*; D007668:Kidney / Q000187:drug effects* / Q000201:enzymology; D008094:Lithium / Q000627:therapeutic use*; D008297:Male; D011863:Radioimmunoassay; D013997:Time Factors
D008094:Lithium; D007610:Kallikreins